- Disease
- Tuesday, 23 Jun 2020
Agenus Cell Therapy and Checkpoint Antibody Combinations Show Curative Preclinical Efficacy at AACR 2020
Agenus Inc., an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, announced that it will make a scientific presentation today on optimal anti-cancer combinations with Fc enhanced anti-CTLA-4, AGEN1181, at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting.
"AGEN1181 is an Fc-engineered anti-CTLA-4 that has shown exciting clinical activity in an early phase 1 clinical trial, which was recently presented at ASCO," said Dr. Antoine Tanne, Lead Scientist, Agenus Immune Biology Team. "Today, at AACR, we report that combinations with AGEN1181 demonstrate curative responses in preclinical models resistant to anti-PD-1. These data illustrate the potential of combining allogeneic cell therapies with checkpoint antibodies, such as AGEN1181, to deliver curative benefit in difficult to treat settings."
Related Industry Updates
$400 billion in market value Erased from Shanghai’s benchmark index after anxiety over the coronavirus
Feb 04, 2020
CDC says, Hantavirus isn't a global public health threat
Mar 25, 2020
206 Japanese nationals evacuated from Wuhan: 4 of them reported Sick with fever or coughing
Jan 29, 2020
Nordic Nanovector's Betalutin® Receives Fast-track Designation from US FDA for Marginal Zone Lymphoma
Jun 29, 2020
Coronavirus Fears Drove Selling on the Shanghai's Stock Exchange
Feb 03, 2020
Young Investigators awarded $200k to study how the body’s own defense mechanisms may be used in the fight against lung cancer
Dec 06, 2019
Managing Your Orthopaedic Care during the COVID-19 Pandemic
May 06, 2020
Follow us on
